tbuckley/cabot-search huggingface dataset:
Gradually Worsening Pruritic Plaques
Authors: Hoda Daher, Basim Towfiq, Samer Al Hadidi
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
P3.01-010 Primary Giant Cell Carcinomas of the Lung: Study of Seven Cases
Authors: Lourdes Gutierrez Sanz, Paloma Martin Acosta, Clara Salas Anton, Ana Isabel Fernandez Diaz, Diego Garcia Fresnadillo, Fernando Fabio Franco, Ana Lopez Gonzalez, David Petite Felipe, Mariano Provencio Pulla
Journal: Journal of Thoracic Oncology (2017)
Lamivudine: fading into the mists of time
Authors: Jonggi Choi, Young-Suk Lim
Journal: Clinical and Molecular Hepatology (2017)

See the Original "Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B" on page 331.
Declining Rates of Hospitalization for Selected Cardiovascular Disease Conditions Among Adults Aged ≥35 Years With Diagnosed Diabetes, U.S., 1998–2014
Authors: Nilka Ríos Burrows, YanFeng Li, Edward W. Gregg, Linda S. Geiss
Journal: Diabetes Care (2017)

OBJECTIVE Reductions in heart attack and stroke hospitalizations are well documented in the U.S. population with diabetes. We extended trend analyses to other cardiovascular disease (CVD) conditions, including stroke by type, and used four additional years of data. RESEARCH DESIGN AND METHODS Using 1998–2014 National (Nationwide) Inpatient Sample (NIS) data, we estimated the number of discharges having acute coronary syndrome (ACS) (ICD-9 codes 410–411), cardiac dysrhythmia (427), heart failure (428), hemorrhagic stroke (430–432), or ischemic stroke (433.x1, 434, and 436) as first-listed diagnosis and diabetes (250) as secondary diagnosis. Hospitalization rates for adults aged ≥35 years were calculated using estimates from the population with and the population without diabetes from the National Health Interview Survey (NHIS) and age-adjusted to the 2000 U.S. standard population. Joinpoint regression was used to analyze trends and calculate an average annual percentage change (AAPC) with 95% confidence limits (CLs). RESULTS From 1998 to 2014, in the population with diabetes, age-adjusted hospitalization rates declined significantly for ACS (AAPC −4.6% per year [95% CL −5.3, −3.8]), cardiac dysrhythmia (−0.7% [−1.1, −0.2]), heart failure (−3.6% [−4.6, −2.7]), hemorrhagic stroke (−1.1% [−1.4, −0.7]), and ischemic stroke (−2.9% [−3.9, −1.8]). In the population without diabetes, rates also declined significantly for these conditions, with the exception of dysrhythmia. By 2014, rates in the population with diabetes population remained two to four times as high as those for the population without diabetes, with the largest difference in heart failure rates. CONCLUSIONS CVD hospitalization rates declined significantly in both the population with diabetes and the population without diabetes. This may be due to several factors, including new or more aggressive treatments and reductions in CVD risk factors and CVD incidence.
Association of Exercise Preconditioning With Immediate Cardioprotection
Authors: Dick H. J. Thijssen, Andrew Redington, Keith P. George, Maria T. E. Hopman, Helen Jones
Journal: JAMA Cardiology (2017)

Exercise reduces the risk of cardiovascular events, including through an underrecognized, clinically useful form of acute cardioprotection accessible after a single episode of exercise, which is called cardiovascular preconditioning.Preclinical evidence shows that 1 to 3 episodes of exercise per week will provide strong cardioprotection; gradual, modest cardiovascular risk factor modification or physiological artery remodeling cannot fully explain these benefits. This review highlights preclinical evidence that acute exercise-induced cardiac preconditioning has the ability to activate multiple pathways to confer immediate protection against ischemic events, reduce the severity of potentially lethal ischemic myocardiac injury, and act as a physiological first line of defense.Independent of the protective benefits of long-term exercise training on risk factors and adaptation of the cardiovascular system, cardiovascular preconditioning may contribute to the immediate cardioprotection of exercise. In practical terms, this means that 1 episode of exercise can create clinically relevant cardioprotection.
Acceptability and effects of values-based outpatient advance care planning (ACP) in gastrointestinal (GI) cancers.
Authors: Andrew S. Epstein, Eileen Mary O'Reilly, Angelo E. Volandes, Elyse Shuk, Danielle R. Romano, William Breitbart
Journal: Journal of Clinical Oncology (2017)

9 Background: We developed and validated the values questions for the Person-Centered Oncologic Care and Choices (P-COCC) ACP intervention, which combines an informational care goals video with a patient values interview. Herein, we studied (primarily) the acceptability of P-COCC, and (secondarily) its effects on wellbeing and decisional conflict. Methods: Patients (pts): English-speaking with GI cancer, ≤ monthly followup in MSK medical oncology clinics and believed by their oncologist able to complete study measures and survive 1-12 months. Consented pts randomized 2:2:1 to P-COCC vs. video alone (V) vs. usual care (UC). Questionnaires: administered baseline and at next follow-up visit on validated measures of wellbeing, and on follow-up only, decisional conflict. P-COCC arm pts also completed 3 Likert scales (was the intervention helpful, comfortable and recommended to others?); a positive score on ≥1 of 3 indicated acceptability for that pt. Results: During screening from 9/2014-11/2016, 202 pts were approached. 51 (25%) declined participation (most common reason, N = 31 = not wanting to discuss the topic). 151 consented and were randomized; 99 (66% of the 151) completed study measures (most common attrition reason, N = 34 = disease progression or death). Of the 99, 63% male; mean age 61 years; mean ECOG PS 1; most common cancers colorectal, gastroesophageal, and pancreatic. The primary aim was met: Among 33 pts, 32 (97%, 95%CI: 0.84-0.99, p &lt; 0.001) rated P-COCC acceptable. Mean distress scores (0-10) increased (0.43) in the P-COCC arm but decreased in the V (-0.04) and UC (-0.21) arms (p = 0.03 and 0.04, P-COCC vs V and UC, respectively). There were no significant pre-post change scores on other measures of wellbeing (anxiety, depression, stress, acceptance, QOL), or intergroup differences in decisional conflict. Qualitatively, P-COCC interviews revealed pt concerns, and desires for support and QOL. Conclusions: Our values-based ACP paradigm is acceptable but may increase distress in GI cancer outpatients. Further studies are investigating underpinnings and follow-up duration of these results, and ways to best support cancer patients (with any cancers, and regardless of prognosis) in ACP. Clinical trial information: NCT01912131.
Organizational Structure and Activities of State Cancer Programs<xref ref-type="fn" rid="fn1"><sup>1</sup></xref>
Authors: James W. Hawkins
Journal: JNCI Journal of the National Cancer Institute (1944)

Journal Article Organizational Structure and Activities of State Cancer Programs Get access James W. Hawkins James W. Hawkins passed assistant surgeon National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 4, Issue 4, February 1944, Pages 347–350, https://doi.org/10.1093/jnci/4.4.347 Published: 01 February 1944
Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies <i>In Vivo</i>
Authors: Hong Qin, Guowei Wei, Ippei Sakamaki, Zhenyuan Dong, Wesley A. Cheng, D. Lynne Smith, Feng Wen, Han Sun, Kunhwa Kim, Soungchul Cha, Laura Bover, Sattva S. Neelapu, Larry W. Kwak
Journal: Clinical Cancer Research (2017)

Purpose: mAbs such as anti-CD20 rituximab are proven therapies in B-cell malignancies, yet many patients develop resistance. Novel therapies against alternative targets are needed to circumvent resistance mechanisms. We sought to generate mAbs against human B-cell-activating factor receptor (BAFF-R/TNFRSF13C), which has not yet been targeted successfully for cancer therapy.Experimental Design: Novel mAbs were generated against BAFF-R, expressed as a natively folded cell surface immunogen on mouse fibroblast cells. Chimeric BAFF-R mAbs were developed and assessed for in vitro and in vivo monotherapy cytotoxicity. The chimeric mAbs were tested against human B-cell tumor lines, primary patient samples, and drug-resistant tumors.Results: Chimeric antibodies bound with high affinity to multiple human malignant B-cell lines and induced potent antibody-dependent cellular cytotoxicity (ADCC) against multiple subtypes of human lymphoma and leukemia, including primary tumors from patients who had relapsed after anti-CD20 therapy. Chimeric antibodies also induced ADCC against ibrutinib-resistant and rituximab-insensitive CD20-deficient variant lymphomas, respectively. Importantly, they demonstrated remarkable in vivo growth inhibition of drug-resistant tumor models in immunodeficient mice.Conclusions: Our method generated novel anti-BAFF-R antibody therapeutics with remarkable single-agent antitumor effects. We propose that these antibodies represent an effective new strategy for targeting and treating drug-resistant B-cell malignancies and warrant further development. Clin Cancer Res; 24(5); 1114-23. ©2017 AACR.
Fiber modification enhancement augments antitumor effect of conditionally replicative adenovirus upon systemic administration in orthotopic pancreatic cancer model
Authors: Pedro J. Ramirez, Julia G. Davydova, Selwyn M. Vickers, David T. Curiel, Masato Yamamoto
Journal: Cancer Research (2006)

2990   Pancreatic cancer is most often diagnosed at an unresectable stage due to metastasis. Thus, there is a high demand for the development of novel therapeutic modalities for systemic usage. While conditionally replicative adenovirus (CRAd) is promising candidate, poor expression of adenoviral primary receptor has been a large obstacle for getting requisite tumor transduction in this tumor context. We have reported that the incorporation of RGD4C motif into adenoviral HI-loop (RGD modification) and substitution of Ad5 fiber-knob region with Ad3 knob (Ad5/3 modification) enhances the CRAd efficiency upon intratumoral injection. However, it has been questioned if the infectivity enhancement is really beneficial for  in vivo  anti-tumor effect in the condition closer to the patient situation. In this study, we analyzed the effect of the adenoviral fiber modifications upon systemic vector administration by using orthotopic pancreatic cancer xenograft model. In order to analyze tumor transduction efficiency, the luciferase expression vectors with normal-Ad5, RGD-modified, and Ad5/3 modified fibers were employed. The cyclooxygenase (COX)-2 promoter-based CRAd and its fiber modified versions were used for the analyses of  in vivo  anti-tumor effect. To establish the orthotopic pancreatic cancer model, an Hs766T subcutaneous xenograft was established in a nude mouse first. Then, the small pieces (1mm 3 ) made from this parental tumor were transplanted into pancreatic bed of other nude mice. The viruses were injected from tail vein 3 days after tumor transplantation. For transduction assay, luciferase activity was analyzed 2 days after vector administration. For the anti-tumor effect, the mice were sacrificed 28 days after CRAd administration.  In vitro , 5/3 modified CRAds exhibited remarkably higher viral replication compared to fiber unmodified counterparts in pancreatic cancer cell lines. As for  in vivo  tumor transduction, only Ad5/3 modified vector showed significantly (8 times) higher transduction compared to the background. This tumor transduction enhancement was also observed in pancreatic cancer subcutaneous xenografts upon systemic vector administration. When CRAds were injected systemically to assess the therapeutic effect in the mice with orthotopic tumors, the volume of the tumor treated with 5/3 CRAd COX-2 was significantly lower than that with non-replicative control virus, and comparable to non-selectively replicating wild type Ad. In the harvested tumors, the viral copy number of the 5/3 COX-2 CRAd was significantly high, even in comparison with non-selective wild type Ad. In conclusion, Ad5/3 modification enhanced the therapeutic effect of systemically administered CRAd. This result suggests the benefits of adenoviral tropism modification as a way to achieve therapeutic effect in clinically relevant settings.
Diagnostic Testing for Obstructive Sleep Apnea in Adults
Authors: Babak Mokhlesi, Adam S. Cifu
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Strengths, altered investment, risk management, and other elaborations on the behavioural constellation of deprivation
Authors: Gillian V. Pepper, Daniel Nettle
Journal: Behavioral and Brain Sciences (2017)

Abstract We are grateful to have received so many insightful commentaries from interested colleagues regarding our proposed behavioural constellation of deprivation (BCD) and our thoughts on its causes and consequences. In this response article, we offer some clarifications regarding our perspective and tackle some common misperceptions, including, for example, assumptions that the BCD is adaptive and that it should include all behaviours that vary with socioeconomic status. We then welcome some excellent proposals for extensions and modifications of our ideas, such as the conceptualisation of the BCD as a risk-management strategy and the calls for a greater focus on strengths and differential investment rather than deficits and disinvestment. Finally, we highlight some insightful explorations of the implications of our ideas for ethics, policy, and practice.
Agreement of different reference equations to classify patients with COPD as having reduced or preserved 6MWD
Authors: F.V.C. Machado, G.W. Bisca, A.A. Morita, A. Rodrigues, V.S. Probst, K.C. Furlanetto, F. Pitta, N.A. Hernandes
Journal: Pulmonology (2017)

Interpretation of the six-minute walk distance (6MWD) is enhanced by using recommended reference equations. Whenever possible, the choice of equation should be region-specific. A potential problem is that different equations for the 6MWD may have been developed for the same population, and it may be complicated to choose the most suitable.
P1.03-044 EUS-Guided Sampling of Mediastinal Lymph Nodes and Abdominal Lesions in Lung Cancer
Authors: Toyoaki Hida, Yuko Oya, Kosuke Tanaka, Hiromi Furuta, Naohiro Watanabe, Tatsuya Yoshida, Junichi Shimizu, Yoshitsugu Horio, Kazuo Hara, Yasushi Yatabe
Journal: Journal of Thoracic Oncology (2017)
Prevalence, associated factors, outcomes and transmission of extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in São Paulo, Brazil: a cross-sectional study
Authors: J.F. Gallo, J.M.W. Pinhata, V. Simonsen, V.M.N. Galesi, L. Ferrazoli, R.S. Oliveira
Journal: Clinical Microbiology and Infection (2017)
Evaluation of the Breast Cancer Index in patients with HER2+/HR+ breast cancer for risk of late recurrence and potential extended endocrine benefit.
Authors: Ruth O'Regan, Brock Schroeder, Nichole Renee Blatner, Catherine A. Schnabel
Journal: Journal of Clinical Oncology (2015)

595 Background: Hormone-receptor positive (HR+), early stage breast cancer patients (pts) are at risk for late ( > 5 year) distant recurrence (DR) and are now considered for extended (10 year) endocrine therapy (EET) to prevent late disease relapse. Approximately 50% of all HER2+ breast cancer pts are also HR+. Clinical trials investigating the benefit of EET to reduce late DR have included HER2+/HR+ pts, but subset analyses in comparison to HER2-/HR+ have been limited. Breast Cancer Index (BCI) is a gene expression based assay validated to 1) assess risk of late DR, and 2) predict benefit from EET using the endocrine response biomarker HoxB13/IL17BR (H/I). This study compared BCI results and clinicopathologic factors in HER2+/HR+ vs HER2-/HR+ breast cancer. Methods: Consecutive cases with known HER2 status (N = 1182) submitted for BCI clinical testing were analyzed for pt characteristics and BCI reporting rates according to HER2 status. Fisher’s test was used to compare results between subgroups. Results: 12% of BCI testing was conducted on HER2+/HR+ pts. Tumor size distribution was similar for HER2+ and HER2- cohorts (P = 0.9). In converse, the HER2+ cohort was comprised of a higher proportion of grade 3 (51% vs 17%; P < 0.001) and ER+/PR- tumors (24% vs 7%; P < 0.001). In regards to risk of late DR, 3 times more tumors were classified as BCI High-Risk in the HER2+ cohort compared to the HER2- cohort (59% vs 19%, P < 0.001; Table 1). Twice as many HER2+ were predicted to benefit from EET compared to the HER2- cohort (High H/I; 69% vs 38%, P < 0.001; Table 1). Conclusions: BCI classifies a higher proportion of HER2+/HR+ tumors into a high-risk group compared to those that are HER2-/HR+, yet a subset of HER2+ tumors are classified as low-risk. Additionally, a significant proportion of the HER2+ cohort was predicted to benefit from ETT. Further studies to validate the ability of BCI to predict benefit of EET in HER2+/HR+ pts are warranted. BCI and H/I categorizations by HER2 status. BCI Risk Classification HER2+ Cohort (N=140) HER2- Cohort (N=1042) Low 18 (13%) 564 (54%) Intermediate 40 (29%) 283 (27%) High 82 (59%) 195 (19%) H/I Categorization Low 45 (32%) 646 (62%) High 95 (69%) 396 (38%)
Abstract 17562: Automatic Quality Assessment of Echo Apical 4-chamber Images Using Computer Deep Learning
Authors: Christina Luong, Amir Abdi, John Jue, Ken Gin, Sarah Fleming, Purang Abolmaesumi, Teresa Tsang
Journal: Circulation (2016)

Background: Echocardiography is a noninvasive imaging modality that allows for assessment of cardiac structure and function for clinical decision-making. However, scanning is a resource intensive t...
Adherence to Methodological Standards in Research Using the National Inpatient Sample
Authors: Rohan Khera, Suveen Angraal, Tyler Couch, John W. Welsh, Brahmajee K. Nallamothu, Saket Girotra, Paul S. Chan, Harlan M. Krumholz
Journal: JAMA (2017)

Publicly available data sets hold much potential, but their unique design may require specific analytic approaches.To determine adherence to appropriate research practices for a frequently used large public database, the National Inpatient Sample (NIS) of the Agency for Healthcare Research and Quality (AHRQ).In this observational study of the 1082 studies published using the NIS from January 2015 through December 2016, a representative sample of 120 studies was systematically evaluated for adherence to practices required by AHRQ for the design and conduct of research using the NIS.None.All studies were evaluated on 7 required research practices based on AHRQ's recommendations and compiled under 3 domains: (1) data interpretation (interpreting data as hospitalization records rather than unique patients); (2) research design (avoiding use in performing state-, hospital-, and physician-level assessments where inappropriate; not using nonspecific administrative secondary diagnosis codes to study in-hospital events); and (3) data analysis (accounting for complex survey design of the NIS and changes in data structure over time).Of 120 published studies, 85% (n = 102) did not adhere to 1 or more required practices and 62% (n = 74) did not adhere to 2 or more required practices. An estimated 925 (95% CI, 852-998) NIS publications did not adhere to 1 or more required practices and 696 (95% CI, 596-796) NIS publications did not adhere to 2 or more required practices. A total of 79 sampled studies (68.3% [95% CI, 59.3%-77.3%]) among the 1082 NIS studies screened for eligibility did not account for the effects of sampling error, clustering, and stratification; 62 (54.4% [95% CI, 44.7%-64.0%]) extrapolated nonspecific secondary diagnoses to infer in-hospital events; 45 (40.4% [95% CI, 30.9%-50.0%]) miscategorized hospitalizations as individual patients; 10 (7.1% [95% CI, 2.1%-12.1%]) performed state-level analyses; and 3 (2.9% [95% CI, 0.0%-6.2%]) reported physician-level volume estimates. Of 27 studies (weighted; 218 studies [95% CI, 134-303]) spanning periods of major changes in the data structure of the NIS, 21 (79.7% [95% CI, 62.5%-97.0%]) did not account for the changes. Among the 24 studies published in journals with an impact factor of 10 or greater, 16 (67%) did not adhere to 1 or more practices, and 9 (38%) did not adhere to 2 or more practices.In this study of 120 recent publications that used data from the NIS, the majority did not adhere to required practices. Further research is needed to identify strategies to improve the quality of research using the NIS and assess whether there are similar problems with use of other publicly available data sets.
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Authors: Paul K. Whelton, Robert M. Carey, Wilbert S. Aronow, Donald E. Casey, Karen J. Collins, Cheryl Dennison Himmelfarb, Sondra M. DePalma, Samuel Gidding, Kenneth A. Jamerson, Daniel W. Jones, Eric J. MacLaughlin, Paul Muntner, Bruce Ovbiagele, Sidney C. Smith, Crystal C. Spencer, Randall S. Stafford, Sandra J. Taler, Randal J. Thomas, Kim A. Williams, Jeff D. Williamson, Jackson T. Wright
Journal: Journal of the American College of Cardiology (2017)